Pharmacokinetic analysis of antibiotic adsorption (vancomycin and teicoplanin) by the Lixelle extracorporeal unit

International Journal of Artificial Organs

Volumn 38, Issue 1, 2015, Pages 8-12

  Sartori, Marco ^a,c   Day, Sonya ^a   De Rosa, Silvia ^a   Ricatti, Maria G ^a   Nalesso, Federico ^a,b   Zancato, Mirella ^c   Ronco, Claudio ^a,b  

^a International Renal Research Institute Vicenza (IRRIV)   (Italy)

^b SAN BORTOLO HOSPITAL   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Dialysis; Dose; Glycopeptide; Gram positive; Hemoperfusion; Staphylococcus

Indexed keywords

ANTIBIOTICS; IMMUNOLOGY; PHARMACOKINETICS;

% REDUCTIONS; DOSE; GLYCOPEPTIDES; GRAM POSITIVE; HEMOPERFUSION; PHARMACOKINETIC ANALYSIS; PHARMACOKINETIC PROPERTIES; STAPHYLOCOCCUS; TEICOPLANIN; VANCOMYCIN;

ADSORPTION;

TEICOPLANIN; VANCOMYCIN;

ARTICLE; DRUG ADSORPTION; FLOW RATE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HEMODIALYSIS; HEMOPERFUSION; SIMULATION; ADSORPTION; DEVICES; DOSE RESPONSE; DRUG EFFECTS; HEMOFILTRATION; HUMAN; IN VITRO STUDY; PHYSIOLOGY; PROCEDURES; RENAL REPLACEMENT THERAPY; SENSITIVITY AND SPECIFICITY;

ADSORPTION; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMOFILTRATION; HEMOPERFUSION; HUMANS; IN VITRO TECHNIQUES; RENAL DIALYSIS; SENSITIVITY AND SPECIFICITY; TEICOPLANIN; VANCOMYCIN;

EID: 84928202949     PISSN: 03913988     EISSN: 17246040     Source Type: Journal    
DOI: 10.5301/ijao.5000383     Document Type: Article

References (32)

1. Van Bambeke F. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr Opin Pharmacol. 2004;4(5):471-478.
2. Guzek A, Korzeniewski K, Nitsch-Osuch A, Rybicki Z, Prokop E. In vitro susceptibility of Staphylococci and Enterococci to vancomycin and teicoplanin. Adv Exp Med Biol. 2013;788: 125-132.
3. Reynolds PE. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Dis. 1989;8(11): 943-950.
4. Borghi A, Coronelli C, Faniuolo L, Allievi G, Pallanza R, Gallo GG. Teichomycins, new antibiotics from Actinoplanes teichomyceticus nov. sp. IV. Separation and characterization of the components of teichomycin (teicoplanin). J Antibiot (Tokyo). 1984;37(6):615-620.
5. Pfeiffer RR. Structural features of vancomycin. Rev Infect Dis. 1981;3(suppl):S205-S209.
6. Barna JC, Williams DH. The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu Rev Microbiol. 1984;38:339-357.
7. Matzke GR, Aronoff GR, Atkinson AJ, et al. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80(11):1122-1137.
8. Barth RH, DeVincenzo N. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney Int. 1996;50(3):929-936.
9. Soto Guerrero Y, Hernández Castillo R, Santiago E, et al. Evaluation of a vancomycin dosing regimen for patients on high flux hemodialysis: an observational study. Bol Asoc Med P R. 2012; 104(3):10-14.
10. Vandecasteele SJ, De Vriese AS. Vancomycin dosing in patients on intermittent hemodialysis. Semin Dial. 2011;24(1): 50-55.
11. Papaioannou MG, Marinaki S, Pappas M, et al. Pharmacokinetics of teicoplanin in patients undergoing chronic haemodialysis. Int J Antimicrob Agents. 2002;19(3):233-236.
12. Homma N, Gejyo F, Hasegawa S, et al. Effects of a new adsorbent column for removing beta-2-microglobulin from circulating blood of dialysis patients. Contrib Nephrol. 1995;112: 164-171.
13. Yamamoto S, Kazama JJ, Narita I, Naiki H, Gejyo F. Recent progress in understanding dialysis-related amyloidosis. Bone. 2009;45(Suppl 1):S39-S42.
14. Gejyo F, Teramura T, Ei I, et al. Long-term clinical evaluation of an adsorbent column (BM-01) of direct hemoperfusion type for beta 2-microglobulin on the treatment of dialysis-related amyloidosis. Artif Organs. 1995;19(12):1222-1226.
15. Gejyo F, Kawaguchi Y, Hara S, et al. Arresting dialysis-related amyloidosis: a prospective multicenter controlled trial of direct hemoperfusion with a beta2-microglobulin adsorption column. Artif Organs. 2004;28(4):371-380.
16. Furuyoshi S, Nakatani M, Taman J, Kutsuki H, Takata S, Tani N. New adsorption column (Lixelle) to eliminate beta2-microglobulin for direct hemoperfusion. Ther Apher. 1998;2(1):13-17.
17. Kutsuki H. beta(2)-Microglobulin-selective direct hemoperfusion column for the treatment of dialysis-related amyloidosis. Biochim Biophys Acta. 2005;1753(1):141-145.
18. Oda S, Hirasawa H, Shiga H, et al. Cytokine adsorptive property of various adsorbents in immunoadsorption columns and a newly developed adsorbent: an in vitro study. Blood Purif. 2004;22(6):530-536.
19. Sartori M, Sharma A, Neri M, et al. New option for the treatment of hyperbilirubinemia: in vitro direct hemoperfusion with the Lixelle S-35. Int J Artif Organs. 2014;37(11):816-823.
20. Maher JF. Principles of dialysis and dialysis of drugs. Am J Med. 1977;62(4):475-481.
21. De Bock V, Verbeelen D, Maes V, Sennesael J. Pharmacokinetics of vancomycin in patients undergoing haemodialysis and haemofiltration. Nephrol Dial Transplant. 1989;4(7):635-639.
22. Vandecasteele SJ, De Vriese AS. Recent changes in vancomycin use in renal failure. Kidney Int. 2010;77(9):760-764.
23. Martin JH, Norris R, Barras M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. Clin Biochem Rev. 2010;31(1):21-24.
24. Wilson AP. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet. 2000;39(3):167-183.
25. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42Suppl 1:S35-S39.
26. Keers RN, Williams SD, Cooke J, Ashcroft DM. Prevalence and nature of medication administration errors in health care settings: a systematic review of direct observational evidence. Ann Pharmacother. 2013;47(2):237-256.
27. Kiekkas P, Karga M, Lemonidou C, Aretha D, Karanikolas M. Medication errors in critically ill adults: a review of direct observation evidence. Am J Crit Care. 2011;20(1):36-44.
28. Fanos V, Mussap M, Khoory BJ, Vecchini S, Plebani M, Benini D. Renal tolerability of teicoplanin in a case of neonatal overdose. J Chemother. 1998;10(5):381-384.
29. Cavalcanti AB, Goncalves AR, Almeida CS, Bugano DD, Silva E. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev. 2010;(6):CD007022.
30. Neville LO, Baillod R, Grady D, Brumfitt W, Hamilton-Miller JM. Teicoplanin in patients with chronic renal failure on dialysis: microbiological and pharmacokinetic aspects. Int J Clin Pharmacol Res. 1987;7(6):485-490.
31. Whitehouse T, Cepeda JA, Shulman R, et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. J Antimicrob Chemother. 2005;55(3):333-340.
32. Kaneko T, Kudo M, Okumura T, et al. Successful treatment of digoxin intoxication by haemoperfusion with specific columns for beta2-microgloblin-adsorption (Lixelle) in a maintenance haemodialysis patient. Nephrol Dial Transplant. 2001;16(1):195-196.